Flavoprotein : Develop Into A Skilled Professional In 6 Simple Moves

86 and 0.8, respectively[34]. Jung et al[36] has shown that liver stiffness is also useful as a part of a predictive model that identifies patients that are at risk for late recurrence after curative resection of HCC. On multivariate analysis, patients with older age, male sex, heavy alcohol consumption (> 80 g/d), lower serum albumin, HBe antigen positivity and LSM > 8 kPa were at a significantly greater risk of HCC development. LIVER ELASTOGRAPHY IN THE PREDICTION OF THE SURVIVAL OF THE PATIENTS WITH CHRONIC LIVER DISEASES Liver stiffness, expressing the severity of the liver damage, Flavoprotein is correlated with hepatic events and death. It has been shown by many studies that measuring liver elasticity one can predict the survival of a patient[37-40]. In the study conducted by Wong et al[37], they found age, Hui index and liver stiffness to be independent predictors of hepatic event - free survival. The same study showed that the worsening of the liver stiffness and Hui index at a follow up visit compared to baseline predicted a hepatic event. Pang et al[38] found that liver stiffness by TE was an independent predictor of complications (hazard ratio 1.05 per kPa; 95%CI: 1.03-1.06), Rapamycin clinical trial with the 2-year incidence rates of death or hepatic complications of 2.6%, 9%, 19%, and 34% in patients with liver stiffness ABT-263 chemical structure CONCLUSION In the past 10 years, liver ultrasound elastography struggled and succeeded to partially replace liver biopsy for the purpose of staging the liver diseases regardless of their etiology. However, as the method became more widely available and because the actual quest of the clinician is to evaluate as completely as possible the extent of the liver damage, its complications and if possible, even to predict an outcome, LSM was studied recently for these purposes also. It is now known that cirrhosis has a complex and dynamic pathologic spectrum. The average risk of progressing from compensated to decompensated cirrhosis is 6%-9% per year[41]. Survival in the compensated state is of an average of 12 years, while in the decompensated state the median survival is of only 2 years[41].